The US Food and Drug Administration (FDA) has cleared CryoPen 's new GY2 Cryosurgical system for use in gynecology.
The GY2 Cryosurgical system, which delivers treatment at -105° Celsius, facilitates medical professionals to ablate Cervical Intraepithelial Neoplasia (CIN) grades 1 and 2 cancer, without the traditional use of dangerous cryogenic gasses or liquids.
The company said, if detected earlier cervical cancer can be prevented and treated.
CryoPen president Michael Haas said GY2 System can make a difference in areas that are underserved by gas delivery including developing countries,
"Many countries have barred the use of nitrous oxide because of its ozone depleting and greenhouse attributes," Haas added.